Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
PRIME MINISTER Keir Starmer congratulated Donald Trump after the Republican claimed victory in the US presidential election, and said he looked forward to working with him.
"I look forward to working with you in the years ahead," Starmer said on X on Wednesday (6).
"I know that the UK-US special relationship will continue to prosper on both sides of the Atlantic for years to come."
He was among the first world leaders to issue a congratulatory message soon after Trump addressed a rally in Florida.
Starmer said the "special relationship" between the UK and the US would continue to prosper under the new American administration after Trump clinched crucial battleground states in the US overnight.
According to reports, 267 electoral votes had gone to Republican candidate Trump and 224 to Democratic party's Kamala Harris. Trump was just three votes short of a victory.
"Congratulations President-elect Trump on your historic election victory. I look forward to working with you in the years ahead,” Starmer said in a statement released by 10 Downing Street in London.
"As the closest of allies, we stand shoulder to shoulder in defence of our shared values of freedom, democracy and enterprise,” he said.
Starmer had met Trump for the first time over a private dinner during a visit to New York for the United Nations General Assembly in September.
"I spent time in New York with President Trump, had dinner with him and my purpose in doing that was to make sure that between the two of us we established a good relationship, which we did, and we’re grateful for him for making the time,” he said at the time.
It was followed by some controversy during the US election campaign after the Trump campaign filed a legal complaint against Labour party officials travelling to US battleground states to volunteer for Trump's Democrat rival Harris.
Labour leader Starmer was forced to reiterate that he had a “good relationship” with Trump, which would not be jeopardised by the complaint.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.